Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company focused on oncology genetics testing and information services. This news page aggregates company announcements, conference presentations, financial updates, and other disclosures that relate to NeoGenomics’ role in precision oncology and testing laboratories.
Readers can find earnings and financial news, including quarterly and preliminary full-year revenue updates furnished through press releases and Form 8-K filings. These items describe trends in clinical test volumes, next-generation sequencing (NGS) revenue, and other aspects of the company’s oncology testing business.
The news feed also features scientific and clinical research updates. NeoGenomics regularly announces data presentations at major oncology and hematology meetings, such as the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These updates often highlight molecular residual disease (MRD) studies using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.
In addition, investors and clinicians can follow corporate and governance developments, including board appointments, executive transitions, and participation in investor conferences. Together, these news items provide a view into how NeoGenomics advances its oncology diagnostics platforms, supports pharmaceutical partners and academic collaborators, and manages its public-company responsibilities. For ongoing insight into NEO stock-related developments and oncology testing initiatives, this page serves as a centralized news resource.
NeoGenomics reported a 9% year-over-year increase in consolidated revenue for 2021, reaching $484 million. Excluding COVID-19 PCR testing, revenue rose 16%. The fourth quarter's revenue remained flat at $126 million, with a 3% decline in Clinical Services revenue. Gross profit fell 21.2% to $45.3 million, attributed to higher costs and the end of PCR testing. Full-year net loss was $8 million, a notable shift from previous profits. The company anticipates 2022 revenue of $530-$550 million but projects losses of $133-$118 million.
NeoGenomics, Inc. (NASDAQ: NEO) has appointed Dr. Shashikant Kulkarni as Executive Vice President for Research & Development and Chief Scientific Officer, effective March 7, 2022. Dr. Kulkarni, previously at Baylor Genetics, brings extensive experience in cancer genomics and has served on several regulatory panels. He aims to enhance NeoGenomics' diagnostic capabilities across the cancer care continuum. CEO Mark Mallon highlights Dr. Kulkarni's expertise as pivotal for innovation in precision medicine.
NeoGenomics has announced successful clinical validation of its RaDaR liquid biopsy test for head and neck squamous cell carcinoma (HNSCC), demonstrating 100% specificity and sensitivity. The data published in the British Journal of Cancer showed that all 17 patients tested had detectable circulating tumor DNA (ctDNA) before surgery, and 100% of patients who experienced recurrence were identified with lead times of 108 to 253 days. This highlights the potential of RaDaR for early intervention and personalized therapy planning in cancer treatment.
NeoGenomics, Inc. (NASDAQ: NEO), a leader in cancer-focused genetic testing, announced participation in several institutional investor conferences on February 17, 2022. The management will engage in investor meetings and fireside chats at SVB Leerink's and BTIG's conferences, both available via live webcast on their website. NeoGenomics, headquartered in Fort Myers, FL, operates accredited laboratories across the U.S. and internationally, providing extensive oncology testing services to support cancer diagnosis and treatment.
NeoGenomics, Inc. (NASDAQ:NEO) announced plans to release its fourth quarter and full year 2021 financial results on February 23, 2022. A webcast and conference call are scheduled for 8:30 AM EDT on the same day to discuss the results. Interested parties can access the call by dialing (888) 506-0062 domestically or (973) 528-0011 internationally. NeoGenomics specializes in cancer genetics testing and provides services for clinical trials, operating facilities in multiple locations, including the US and Europe. The company is committed to data protection and utilizing advanced technology.
NeoGenomics, Inc. (NASDAQ:NEO) has announced a strategic partnership with the Biomarker Collaborative to enhance support for cancer patients with specific biomarkers. This initiative enables patients who test positive for lung cancer biomarkers to access a dedicated resource page, offering education and connections to support groups. CEO Mark Mallon emphasized the importance of this partnership in improving patient care and outcomes. Through this collaboration, both patients and oncologists will have clearer insights into relevant biomarker groups crucial for treatment.
NeoGenomics, Inc. (NASDAQ: NEO) announced that its subsidiary, Inivata Limited, received CE mark certification for its RaDaR™ assay, which detects molecular residual disease (MRD) and detects recurrences in patients. This certification allows for clinical use in key territories like the UK and EU. Additionally, Inivata submitted a request for reimbursement for the RaDaR assay under the US MolDX program. RaDaR demonstrates high sensitivity (95%) and specificity (100%) for detecting circulating cancer DNA, marking significant progress in cancer diagnostics.
NeoGenomics, Inc. (NASDAQ:NEO) has appointed Dr. David Eberhard as Chief Medical Officer of its subsidiary Inivata, focusing on liquid biopsy tests, notably the RaDaR™ assay for minimal residual disease detection. Eberhard brings over 20 years of oncology experience, having previously held leadership roles at Illumina and Genomic Health. CEO Mark Mallon emphasized the importance of Eberhard's expertise in maximizing Inivata's assay potential, while Inivata President Clive Morris highlighted his extensive clinical strategy experience as a key asset for advancing their innovative technology.
NeoGenomics, Inc. (NASDAQ:NEO) announced its collaboration with Thermo Fisher Scientific to utilize the Ion Torrent Genexus System for a Phase 1 study focused on myeloid cancers. The Genexus System streamlines the specimen-to-report workflow, enabling result delivery in as little as one day. NeoGenomics gains early access to the Oncomine Myeloid Assay GX v2 to validate its performance. This partnership aims to enhance genomic data delivery speed, improving research capabilities for myeloid cancer treatment development, thus addressing critical patient needs.
NeoGenomics (NASDAQ: NEO) announced its participation in the Stephens Annual Investment Conference 2021 on December 3, 2021, at 9:00am CT, in Nashville, Tennessee. Key executives, including CEO Mark Mallon, will present during the event, which can be accessed via live webcast on the company's investor relations website. NeoGenomics specializes in cancer-focused genetic testing and serves various clients, including pharmaceutical companies. The company operates accredited laboratories across multiple U.S. locations and globally.